Docket: AR226-0459

All documents tagged with this AR226 identifier.

Page 1 of 1 — 2 documents
Title / Summary Year AR226 Docket Hash ID Pages
The document reports on a study conducted by Riker Laboratories, a subsidiary of 3M, which found that cholestyramine treatment significantly enhanced the elimination of carbon-14 labeled FC-95 and FC-143 in male rats, reducing retention in liver, plasma, and red blood cells while increasing fecal excretion. 1930 AR226-0459 pBdB7ayjRQaEzXxNXEm3bj5qB 29
The document reports that cholestyramine treatment significantly enhanced the elimination of carbon-14 labeled FC-95 and FC-143 in male rats, with notable reductions in liver, plasma, and red blood cell concentrations and increased fecal excretion compared to control groups. 1930 AR226-0459 5D24KMdnBNJx2rEQ0LoLLw7V 29